# A Study of Revumenib and Mezigdomide in People With Leukemia

> **NCT07356154** · PHASE1,PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 52 (estimated)

## Conditions studied

- Leukemia
- Acute Leukemia
- Relapse Leukemia
- Refractory Leukemia
- Refractory Acute Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Mixed Phenotype Acute Leukemia

## Interventions

- **DRUG:** Revumenib
- **DRUG:** Mezigdomide

## Key facts

- **NCT ID:** NCT07356154
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2029-01-16
- **Final completion:** 2029-01-16
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07356154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07356154, "A Study of Revumenib and Mezigdomide in People With Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07356154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*